Envisioning hepatitis delta cure without functional hepatitis B cure
Autor:
Soriano, Vicente
; de Mendoza, Carmen
; Barreiro, Pablo
Fecha:
2022Palabra clave:
Revista / editorial:
AIDS reviewsCitación:
Soriano, V., de Mendoza, C., & Barreiro, P. (2022). Envisioning hepatitis delta cure without functional hepatitis B cure. AIDS reviews, 24(4), 200-200.Tipo de Ítem:
Articulo Revista IndexadaDirección web:
https://www.aidsreviews.com/resumen.php?id=1621Resumen:
[abstract not available]
Este ítem aparece en la(s) siguiente(s) colección(es)
Estadísticas de uso
Año |
2012 |
2013 |
2014 |
2015 |
2016 |
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
2024 |
Vistas |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
17 |
39 |
Descargas |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
Ítems relacionados
Mostrando ítems relacionados por Título, autor o materia.
-
Impact of scaling up SARS-CoV-2 vaccination on COVID-19 hospitalizations in Spain
Barandalla, Ignacio ; Alvarez, Carmen ; Barreiro, Pablo; de Mendoza, Carmen; González-Crespo, Rubén ; Soriano, Vicente (Elsevier B.V., 2021)Background: The advent of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines has been associated with a significant decline in coronavirus disease 2019 (COVID-19) hospitalizations and deaths. However, ... -
Hospital admissions in individuals with HTLV-1 infection in Spain
Ramos, José M.; Mendoza, Carmen de; Aguilera, Antonio; Barreiro, Pablo; Benito, Rafael; Eirós, José M.; Soriano, Vicente (AIDS, 06/2020)OBJECTIVE: To examine the clinical burden and disease spectrum, as well as time trends for human T-cell leukemia virus type 1 (HTLV-1) and HTLV type 2 (HTLV-2) hospital admissions. DESIGN: Retrospective, observational study ... -
Long-acting antiretroviral therapy
Soriano, Vicente ; Barreiro, Pablo; Mendoza, Carmen de (Nature Materials, 01/08/2020)Nanoformulations of cabotegravir prodrugs have been developed to prolong the pharmacokinetics of the antiretroviral agent. They can be present in the plasma of mice and non-human primates for a year following a single injection.